GlaxoSmithKline Pharmaceuticals Ltd banner

GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO

Watchlist Manager
GlaxoSmithKline Pharmaceuticals Ltd Logo
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Watchlist
Price: 2 464.8999 INR -1.19% Market Closed
Market Cap: ₹417.6B

EV/EBIT

32.5
Current
12%
Cheaper
vs 3-y average of 37

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
32.5
=
Enterprise Value
₹427.6B
/
EBIT
₹12.2B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
32.5
=
Enterprise Value
₹427.6B
/
EBIT
₹12.2B

Valuation Scenarios

GlaxoSmithKline Pharmaceuticals Ltd is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (37), the stock would be worth ₹2 813.11 (14% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-28%
Maximum Upside
+14%
Average Downside
5%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 32.5 ₹2 464.9
0%
3-Year Average 37 ₹2 813.11
+14%
5-Year Average 37 ₹2 813.11
+14%
Industry Average 25.6 ₹1 940.88
-21%
Country Average 23.3 ₹1 767.1
-28%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
₹427.6B
/
Jan 2026
₹12.2B
=
32.5
Current
₹427.6B
/
Mar 2026
₹13.6B
=
31.5
Forward
₹427.6B
/
Mar 2027
₹15B
=
28.5
Forward
₹427.6B
/
Mar 2028
₹16.1B
=
26.6
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
IN
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
422.6B INR 32.5 40.9
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 29.2 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 21.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.4 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 21.9 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 15.6 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 11.5 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 970 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 9.8 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 10.1 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 8.9 16.8

Market Distribution

In line with most companies in India
Percentile
67th
Based on 2 572 companies
67th percentile
32.5
Low
0.4 — 15.7
Typical Range
15.7 — 34.7
High
34.7 —
Distribution Statistics
India
Min 0.4
30th Percentile 15.7
Median 23.3
70th Percentile 34.7
Max 48 145.1

GlaxoSmithKline Pharmaceuticals Ltd
Glance View

Market Cap
417.6B INR
Industry
Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Ltd., a subsidiary of the global healthcare juggernaut GSK, stands as a pillar in the pharmaceutical industry, with roots deeply entrenched in innovation and a robust pipeline of healthcare products. This company weaves a narrative of relentless pursuit in the creation and distribution of a wide variety of medicines and vaccines, aimed at improving the quality of human life. Operating predominantly in the areas of pharmaceuticals, vaccines, and consumer healthcare, GSK integrates cutting-edge research with strategic collaborations. This enables them to address pressing medical needs, such as respiratory diseases, HIV, infectious diseases, and oncology, amongst others, thereby leveraging their expertise to cater to diverse healthcare demands. The heart of their revenue generation lies in the seamless amalgamation of research acumen and market presence. By investing significantly in research and development, GSK continually introduces groundbreaking therapies and health solutions. The company has adeptly structured its operations to create a strong global presence, which not only involves selling directly to healthcare providers and governments but also innovating its supply chain to maximize reach. Moreover, GSK's astute marketing efforts ensure that their products are not just effective but also attuned to consumer needs. With a focus on sustainable growth and transformative medicines, GSK’s story becomes a testament to how science-driven strategies can forge pathways to a healthier world while simultaneously fueling the company’s economic engine.

GLAXO Intrinsic Value
1 376.6486 INR
Overvaluation 44%
Intrinsic Value
Price ₹2 464.8999
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett